UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Broadens Epilepsy Portfolio With $1.9bn Purchase
Executive Summary
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
You may also be interested in...
Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact
The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.
Zydus Sets Sight On First US Generic Of UCB’s Briviact
Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.
ANDA Sponsors Swarm On Vimpat Blockbuster As Protection Expires
UCB’s Vimpat blockbuster has finally fallen to generic competition in the US, after its intellectual property was skewered by ANDA sponsors as part of a failed challenge before the US Supreme Court in 2018 and 2019.